Arpad Szallasi
Scientific Advisory Member
Diabetes and Endocrinology
PILA PHARMA
Sweden
Biography
Arpad Szallasi is a leading expert on the roles of TRP channels in health and disease. He was the first to provide a biochemical proof for the existence of the vanilloid (capsaicin) receptor, now known as TRPV1. Currently, he is the Medical Director of Hematopathology and Flow Cytometry at Baptist Medical Center, Baptist-MD Anderson Cancer Center, and the Wolfson Children’s Hospital, Jacksonville, Florida.
Research Interest
Arpad Szallasi graduated as veterinarian (DVM). He has profound experience from the life-science industry, whereof more than 10 years were in Diabetes Research & Development at Novo Nordisk A/S, Denmark working with various project teams within the diabetes and obesity research areas with small molecules and peptides including insulin- and GLP-1- analogues. She is the author of several scientific publications with a focus on TRPV1 in diabetes or anti-diabetic agents as well as of patents related to TRPV1 in diabetes and to basal insulin analogues.
